Screener
Polaryx Therapeutics, Inc. PLYX Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Polaryx Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.
The source filing: Polaryx Therapeutics, Inc.’s 10-K, filed March 24, 2026.
- Filed
- Mar 24, 2026, 12:00 AM EDT
- Fiscal year
- FY2025
- Accession
- 0001213900-26-033064
| Line item | As of / December 31, 2025 | As of / December 31, 2024 |
|---|---|---|
| Commitments and contingencies (Note 9) | ||
| Stockholders’ equity: | ||
| Preferred stock: $0.0001 par value, 40,000,000 shares authorized; 0 and 0 shares issued and outstanding at December 31, 2025 and 2024, respectively | — | — |
| Common stock: $0.0001 par value; 560,000,000 shares authorized; 47,343,297 and 41,151,571 shares issued and outstanding at December 31, 2025 and 2024, respectively | 5 | 4 |
| Additional paid-in capital | 104,195 | 95,358 |
| Accumulated deficit | (99,635) | (90,650) |
| Total stockholders’ equity | 4,565 | 4,712 |
| Total liabilities and stockholders’ equity | $5,170 | $5,001 |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Polaryx Therapeutics, Inc.'s common stock?
- Polaryx Therapeutics, Inc. (PLYX) reported common stock of $560M in Q4 2025.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Polaryx Therapeutics, Inc.'s common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude